This is the focus of my lab research and my interest in the field of Alzheimer’s and related dementia. So Alzheimer’s disease is a heterogeneous group of disorders, not a single disorder. Alzheimer’s heterogeneity is manifested in multiple levels, clinically in comorbidity and a wide range of disease trajectories. Neuropathologically, we have co-pathologies. And recently, several teams identified multimodal molecular heterogeneity...
This is the focus of my lab research and my interest in the field of Alzheimer’s and related dementia. So Alzheimer’s disease is a heterogeneous group of disorders, not a single disorder. Alzheimer’s heterogeneity is manifested in multiple levels, clinically in comorbidity and a wide range of disease trajectories. Neuropathologically, we have co-pathologies. And recently, several teams identified multimodal molecular heterogeneity. The molecular subtypes of Alzheimer’s were linked to individual clinical pathological trajectories. And it was suggested that they are driven by diverse risk factors. And by that, giving us mechanistic clues. Moreover, genome-wide association studies keep discovering new loci as the sample size increases, and this points at a new genetic risk that’s present within a subgroup of patients. Our lab work highlights this heterogeneity and illustrates the potential of precision medicine approaches grounded in patient certification and gene-targeted therapeutic strategies. The complexity and heterogeneity is like a winding road. It poses challenges for identifying precise disease mechanisms and consequently for developing effective therapies. So we in the lab leverage on advanced genomic technology, particularly single-cell multi-omics, in order to dissect the molecular underpinnings of Alzheimer’s mechanisms and heterogeneity across diverse populations, and also to pinpoint the cell types that most likely mediate multi-omics molecular profiles. But beyond deepening mechanistic understanding through basic science discovery, these approaches directly support therapeutic innovation, including gene-targeted interventions, like in gene therapy, and omic-based biomarkers. So at the end of the winding road, the end of this journey, will bring hope to the patients that suffer from Alzheimer’s and related dementias.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
